AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

The question of putative mechanisms of action continues to haunt psychopharmacology.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy The following represents disclosure information provided by authors of this ...